Disease Information & Support


The Word:


Generic name Ruxolitinib
Pronunciation RUX-oh-LI-ti-nib
Brand name(s), other common name(s) Jakafi®
Drug type  Kinase inhibitor
How the drug is given By mouth

Ruxolitinib is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

Side effects needing medical attention: Serious allergic reactions (tightness in throat, abnormal swelling/redness or difficulty breathing), some of which may be life-threatening; inflammation of the pancreatitis (stomach pain); abnormal blood clotting (may have headache, pain in leg, arm, or chest); unusual bleeding; liver problems; nausea, vomiting, and abnormal blood sugar levels (may be thirsty or frequently urinate). 

Tuberculosis has been reported in patients receiving ruxolitinib for myelofibrosis.

Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in death, has been reported with ruxolitinib treatment for myelofibrosis. 


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Wednesday, November 27, 2013